Home >  News >  Industry >  Pharma News >  Sun Pharma aims to...

Sun Pharma aims to protect supply chain, preserve cash amid COVID challenges

Shanghvi said that the company is also looking at supply chain protection, ensuring optimum utilisation of its factories and working closely with vendors to ensure continuity of supply while at the same time continuing focus on improving productivity throughout.;

By - Ruchika Sharma
Published On 2020-07-20 06:30 GMT   |   Update On 2020-07-20 06:30 GMT
Advertisement

New Delhi: Drug major Sun Pharma aims to gain market share in all the verticals it is present in amid challenges posed by the coronavirus pandemic, as per a top company official. "Our endeavour will be to gain market share in each of our business by doing better. Despite the near-term uncertainties related to COVID-19, we hope to be able to do better consistently," Sun Pharmaceutical Industries MD Dilip Shanghvi said in an analyst call.

The drug major, which has a presence in around 150 countries, caters to various segments like psychiatry, anti-infectives, neurology, cardiology, oncology, among others.
Shanghvi said that the company is also looking at supply chain protection, ensuring optimum utilization of its factories and working closely with vendors to ensure continuity of supply while at the same time continuing focus on improving productivity throughout.
Advertisement
In times of COVID-19, the Mumbai-based company also looks to focus on cash preservation and finding a way to reduce the overall debt for the company, Shanghvi said.
"You will see that the total borrowings have come down by almost USD 400-plus million (about Rs 3,000 crore) in one year. And we will continue the same focus reducing the overall debt," he noted.
Commenting on the company's plans to expand its domestic business, Sun Pharma Head (India Business) Kirti Ganorkar said the drug firm is in the process of expanding its field force in order to increase its reach.
"We want to expand (field force) by 10 percent. Out of that, 7 percent to 8 percent we have already achieved so that we cover a large number of doctors and we cover some of the territories, which we have not covered," he noted.
At the same time, the company also wants to build new brands and turn its existing brands into mega brands, Ganorkar said.
"We want to introduce new products ahead of the competition. And we want to make products available in the supply chain. So looking at all these factors, long-term will help us to increase our market share," he added.
Things were going in the right direction, but COVID-19 pandemic has put a new challenge for the company, he said.
Commenting on the company's growth plans in the US generics business, Sun Pharma CEO (North America Business) Abhay Gandhi said the drugmaker has a pipeline of 98 ANDAs (Abbreviated New Drug Application) and five NDAs.
"So the pipeline is strong. On pricing, we still see pressure on pricing, and we don't see that abating in the near term or even in the mid-term if I say so. So we keep hoping, but I haven't seen that happening," he noted.
On a question related to Japanese business, Shanghvi said the company continues to look at opportunities to invest in the country.
"The first priority and focus for us, of course, would be to launch Ilumya once it is approved in Japan and for which we would be creating a significant organizational capability," he said.
Besides, the company will continue to look at attractive opportunities, where it can leverage effectively existing presence and look at the opportunity to grow the business, Shanghvi added.
Read also: US: Sun Pharma allegedly dismisses an employee for complaining about improper drug distribution, violation of FDA regulations

Tags:    
Article Source : PTI

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Ruchika Sharma

Ruchika Sharma joined Medical Dialogue as an Correspondent for the Business Section in 2019. She covers all the updates in the Pharmaceutical field, Policy, Insurance, Business Healthcare, Medical News, Health News, Pharma News, Healthcare and Investment. She has completed her B.Com from Delhi University and then pursued postgraduation in M.Com. She can be contacted at editorial@medicaldialogues.in Contact no. 011-43720751

Comments Policy
Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Similar News

Novartis ianalumab Phase III trial meets primary endpoint in immune thrombocytopenia

AbbVie announces USD 195 million investment to expand API manufacturing in US

Padcev plus Keytruda significantly improves survival for certain patients with bladder cancer when given before, after surgery: Pfizer

ITAT Grants Relief to Thermo Fisher in GSK-Linked Slump Sale, Allows Rs 3.07 Cr Depreciation on Goodwill

Novo Nordisk elevates Dr Gaurav Yadav as Cardiometabolic Medical Director for Business Area Africa Medical & Marketing team

Goa unveils lifesaving therapies pricing policy

Novo Nordisk Wegovy approved by USFDA for adults with noncirrhotic MASH with liver fibrosis

Alembic Pharma gets USFDA nod for acne vulgaris cream